MARKET NEWS

Exavir Therapeutics Announces Preclinical Data Demonstrating Complete Elimination of HIV From Human Cells With LNP-Delivered Tat-Targeted CRISPR-Cas9
Finch Therapeutics Announces Positive Topline Data From Phase 2 PRISM-EXT Open-Label Study of Microbiome Therapy for Recurrent C. diff.
Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients With Parkinson’s Disease
CN Bio & iiCON Announce COVID-19 Research Collaboration
Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Milademetan
Synlogic & Ginkgo Bioworks Announce Investigational Synthetic Biotic Medicine for the Treatment of Homocystinuria

  FEATURED EDITORIAL


  COMPANY PROFILE

Founded in 1897, BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to healthcare. BD’s drug delivery systems are designed to protect, package, and deliver drug therapies and to maximize healthcare worker and patient safety. BD is uniquely positioned to offer pre-fillable syringe systems with expertise in drug container interactions, primary container selection, and container/device integration for a variety of drug therapies, including vaccines, chronic diseases treatment, acute care drugs, anticoagulants, and hyaluronic acid. Click here for more.

  EXCLUSIVE ONLINE CONTENT


Mustang Bio Announces Exclusive Worldwide License Agreement With Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy With Curative Potential for RAG1 Severe Combined Immunodeficiency

Mustang Bio Announces Exclusive Worldwide License Agreement With Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy With Curative Potential for RAG1 Severe Combined Immunodeficiency

Mustang Bio, Inc. recently announced that the company has executed an exclusive license agreement with Leiden University Medical Centre (LUMC) for a first-in-class ex vivo lentiviral gene therapy for the….

First Own Gerresheimer Autoinjector - Gerresheimer & Midas Pharma Announce Strategic Partnership

First Own Gerresheimer Autoinjector - Gerresheimer & Midas Pharma Announce Strategic Partnership

Gerresheimer recently announced it has acquired the IP of a new generation cartridge-based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector…

PDC* line Pharma Opens Last Cohort of PDC-Lung-101 Clinical Trial

PDC* line Pharma Opens Last Cohort of PDC-Lung-101 Clinical Trial

PDC*line Pharma recently announced the last cohort of patients has been opened and the first patients were dosed, in the PDC-LUNG-101 Phase 1/2 clinical trial (NCT03970746) with PDC*lung01, the company’s therapeutic cancer….

ESCP Models - Hepatitis C Medications (Part 2), Oral Therapeutics

ESCP Models - Hepatitis C Medications (Part 2), Oral Therapeutics

Part 2 of this series fills in the story starting with the first oral HCV therapeutic, Vertex’s Incivek (telaprevir), which predated the first of the Gilead therapeutics by 2.5 years…

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 24 – Analytical Instruments
December 1 – Formulation Development